RxDoctor Payments DataLook up a doctor →

David Russell

Neurology · New Haven, CTNPI 1548241839

Payments from drug & device makers

$31,164,205in general payments, 2019–2025

Across 790 payments — averaging $39,448 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$17M
  • Eli Lilly$6.2M
  • Biogen$3.2M
  • Roche TCRC, Inc.$2M
  • Neurocrine Biosciences, Inc.$1.1M
  • AbbVie$885K
  • plus $720K from 15 others
$28,352in research payments, 2019–2025

Across 16 payments — averaging $1771.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$24K
  • Biogen$3K
  • F. Hoffmann-la Roche AG$711
  • Neurocrine Biosciences, Inc.$572

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$31,164,205 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Other neurology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →